PDF Cover

Oral Insulin Pills Market

Oral Insulin Pills Market

The market for Oral Insulin Pills was estimated at $2.7 billion in 2024; it is anticipated to increase to $7.2 billion by 2030, with projections indicating growth to around $16.1 billion by 2035.

Report ID:DS1801213
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Medical Device
Oral Insulin Pills
Share
Connect
Report Price: $4,200
Report Summary
Market Data
Methodology
Table of Contents

Global Oral Insulin Pills Market Outlook

Revenue, 2024

$2.7B

Forecast, 2034

$13.7B

CAGR, 2025 - 2034

17.6%

The Oral Insulin Pills industry revenue is expected to be around $3.2 billion in 2025 and expected to showcase growth with 17.6% CAGR between 2025 and 2034. The importance of insulin pills in the pharmaceutical market today cannot be emphasized enough due to various crucial factors like the rising global incidence of diabetes and the continuous development of drug delivery methods alongside an aging population with a higher demand for long term treatment plans. The reliability and effectiveness of insulin in pill form offer an option for patients hesitant about injections supportin ongoing significance and promising opportunities, in the diabetes care sector of pharmaceuticals.

Innovative Oral insulin pills provide an gentle way to administer insulin without the need for injections. They offer a user option that avoids the discomfort of traditional insulin shots by delivering insulin orally while maintaining its effectiveness in the stomach. This feature makes them particularly attractive to the population dealing with diabetes. Their benefits extend beyond managing diabetes to addressing other conditions linked to insulin resistance such, as metabolic syndrome and polycystic ovary syndrome.

Oral Insulin Pills market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Oral Insulin Pills Market Outlook

Market Key Insights

  • The Oral Insulin Pills market is projected to grow from $2.7 billion in 2024 to $13.7 billion in 2034. This represents a CAGR of 17.6%, reflecting rising demand across Medical Treatment of Diabetes, Research & Development, and Geriatric Care.

  • Novo Nordisk, Oramed Pharmaceuticals, and Biocon are among the leading players in this market, shaping its competitive landscape.

  • U.S. and Germany are the top markets within the Oral Insulin Pills market and are expected to observe the growth CAGR of 16.9% to 24.6% between 2024 and 2030.

  • Emerging markets including Brazil, South Korea and South Africa are expected to observe highest growth with CAGR ranging between 13.2% to 18.3%.

  • Transition like Revolution in Diabetic Care is expected to add $1 billion to the Oral Insulin Pills market growth by 2030

    .

  • The Oral Insulin Pills market is set to add $11.0 billion between 2024 and 2034, with manufacturer targeting Type 2 Diabetes & Gestational Diabetes Application projected to gain a larger market share.

  • With The rising prevalence of diabetes, and technological Advancements in Drug Delivery Systems, Oral Insulin Pills market to expand 406% between 2024 and 2034.

oral insulin pills market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Oral Insulin Pills - Country Share Analysis

Opportunities in the Oral Insulin Pills

The need for invasive insulin delivery methods is increasing rapidly in the medical field nowadays as researchers are working on creating small oral insulin pills with controlled release to potentially bring great benefits and improve patient adherence, to treatment plans while also boosting market expansion.

Growth Opportunities in North America and Asia Pacific

The market for Oral insulin pills is substantial in North America. Especially in the United States due to the high rates of diabetes and increasing health consciousness among the population there. The strong healthcare system and ongoing research and development in treatments have led to a growing demand for advanced medications like Oral insulin pills. Key players in the market such as Novo Nordisk and Eli Lilly are making investments, in this region which is heightening competition. The main factors fueling this market are the rising cases of insulin resistance and the growing need for invasive ways to administer insulin. This trend is boosting the demand, for insulin pills.
In the Asia Pacific region. In countries like India and China. There are significant chances for oral insulin tablets due to the increasing number of people with diabetes and the ongoing public health efforts to raise awareness and improve disease management practices in these regions. Despite facing competition from companies such as Oramed and Biocon competing for a slice of the market share pie in this region withi a large patient base offers promising opportunities, for growth. The main factors influencing the market include increasing urbanization trends and lifestyle changes that contribute to a rise, in obesity and diabetes cases. Additionally concurring are government efforts to enhance healthcare infrastructure which are driving the growth of the insulin pills market.

Market Dynamics and Supply Chain

01

Driver: The Rising Prevalence of Diabetes, and Growing Preference for Non-Invasive Treatments

With the rising prevalence of diabetes and the need for more effective treatments on the rise as well; the interest in innovative solutions like oral insulin tablets is also expected to surge too. Compared to the injectable insulin method; oral insulin provides a simpler and less intrusive way of delivery that is also attractive, to a broad range of patients.

As patient-centric care becomes the norm in healthcare, there is also greater emphasis on non-invasive treatment options. Oral insulin pills, with their ease of ingestion and potential for self-administration, align well with these evolving healthcare paradigms, and are also expected to witness substantial uptake.

Advancements in drug delivery methods are also helping make oral insulin pills widely accepted by improving their effectiveness through developments, in Nanotechnology and targeted delivery techniques while enhancing bioavailability—ultimately fuel the growth of the market for these pills.

02

Restraint: Scientific Complexity and Clinical Challenges

Developing insulin pills has proven to be quite challenging due to the complex nature of insulin as a peptide hormone that struggles to survive the acidic stomach environment required for oral intake and faces difficulties in being absorbed through the intestinal wall because of its large size. The obstacles encountered have resulted in prolonged research and clinical trials periods with increased costs and slower product development cycles before reaching the market. Pharmaceutical companies often face challenges when insurance providers are hesitant to cover new treatments, which impacts the demand in the market, and highlights the importance of advancements in hormone tracking for better treatment monitoring and patient outcomes.

03

Opportunity: Penetrating Emerging Markets and Strategic Partnerships with Diabetes Management Companies

Emerging economies offer an opportunity for oral insulin tablets to thrive with the rising number of people diagnosed with diabetes and the growth in healthcare spending in nations like India, China and Brazil paving the way for these advanced diabetes treatments to make a significant impact. The increasing desire among consumers for user friendly insulin delivery methods could lead to a substantial increase in demand for these products, in these areas.

Working together with companies that specialize in diabetes management has the potential to boost the market presence of insulin pills significantly. By forming partnerships with these companies manufacturers of oral insulin pills can incorporate their product into comprehensive solutions, for managing diabetes thus improving the overall appeal of their offerings.

04

Challenge: Uncertainty Regarding Regulatory Approval

Another in the oral insulin pills market is the predictability of regulatory approval. Regulatory bodies such as the Food & Drug Administration have immensely rigorous requirements for the certification of oral medications. Owing to the novelty of this form of insulin delivery, its challenging for manufacturers to anticipate and effectively meet these standards.

Supply Chain Landscape

1

Raw Material Procurement

Eli Lilly and CompanyNovo Nordisk
2

Production & Synthesis

PfizerSanofi
3

Distribution & Marketing

Merck & Co.GlaxoSmithKline
4

Retail & End-users

WalgreensCostco Wholesale
Oral Insulin Pills - Supply Chain

Applications of Oral Insulin Pills in Medical Treatment of Diabetes, Geriatric Care & Research & Development

Medical Treatment of Diabetes : Oral insulin pills are predominantly used in the medical treatment of diabetes, specifically 2 diabetes patients who face difficulty in insulin injection administration due to needle phobia or other complications. The portability and convenience provided by oral insulin technologies, such as oral insulin pills, enable them to improve glycemic control effectively. Leading players like Novo Nordisk have invested significantly in such insulin delivery mechanisms, catering to a large consumer base who prefer this non-invasive mode of treatment. Their market position is strengthened by their extensive research and evidence-based outcomes, directly showcasing the positive impact of oral insulin pills on patient care and diabetes management
Research & Development : Oral insulin pills are widely used in research and development. They provide researchers with a vital tool for understanding and experimenting with insulins impact on the body and its reaction in the digestive system. Several pharmaceutical giants, such as Eli Lilly and Company and Oramed Pharmaceuticals, are focusing on the research and development of oral insulin pills, playing a crucial role in their efforts to push the boundaries of diabetes treatment and perhaps even delay or prevent onset of the disease
Geriatric Care : For elderly patients with 2 diabetes, oral insulin pills present a simplified, less painful alternative to insulin injections. The ease of administration makes them particularly suitable for home-based and non-clinical settings where professional medical supervision may be less consistent or invasive modes of treatment are less feasible.

Recent Developments

Recent developments in the sector of oral insulin pills have prompted a strong wave of anticipated innovation, spurred by technological advancements and the rising global prevalence of diabetes. Oral insulin, seen as an alternative to insulin injections, is gaining significant traction within the healthcare sector. Utilizing novel technologies, prominent pharmaceutical companies are propelling research aimed at leveraging the sizeable potential market share in this fast-evolving industry.

December 2024 : Globulin Pharma commenced phase III trials for its advanced oral insulin pills, reflecting a strategic shift towards non-invasive diabetes treatments
November 2024 : InsulTech Inc. received regulatory approval for its innovative oral insulin pill, marking a major development in insulin delivery technology
September 2024 : Diabetica Solutions announced a strategic partnership with BioFortis Therapeutics to expand the clinical reach of their oral insulin pills, demonstrating the dynamic nature of the market.

Impact of Industry Transitions on the Oral Insulin Pills Market

As a core segment of the Medical Device industry, the Oral Insulin Pills market develops in line with broader industry shifts. Over recent years, transitions such as Revolution in Diabetic Care and Paradigm Shift in Drug Delivery Systems have redefined priorities across the Medical Device sector, influencing how the Oral Insulin Pills market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Revolution in Diabetic Care

With diabetes becoming common worldwide there is a growing need for better treatment options. Surprisingly oral insulin pills are now possible despite doubts about insulins survival in the stomach. This advancement has had an impact on diabetic care allowing patients to avoid the discomfort of injections and improving their adherence, to medication and overall well being and health outcomes. This industry shift has an impact on more than just diabetes care providers; it also affects pharmaceutical companies as well, as healthcare facilities and care technology manufacturers. This industry transition is expected to add $1 billion in the industry revenue between 2024 and 2030.
02

Paradigm Shift in Drug Delivery Systems

The advent of oral insulin pills marked a significant transition towards noninvasive drug delivery systems. This shift in focus from injectionbased to digestivesystembased medication is reshaping the pharmaceutical landscape. Its not only just limited to the diabetes market, but is echoing across different healthcare sectors that require regular medication, such as cardiology, neurology, and oncology.

Related Reports
Loading related reports...